Stockscreener 앱 받기
5.84
3.00%
0.17
시간 외 거래:
5.79
-0.05
-0.86%
전일 마감가:
$5.67
열려 있는:
$5.7
하루 거래량:
3.42M
Relative Volume:
0.97
시가총액:
$1.44B
수익:
$427.68M
순이익/손실:
$-58.06M
주가수익비율:
-24.52
EPS:
-0.2382
순현금흐름:
$-37.50M
1주 성능:
+4.10%
1개월 성능:
-6.26%
6개월 성능:
+0.86%
1년 성능:
+64.51%
1일 변동 폭
$5.70
$5.945
1주일 범위
$5.535
$5.945
52주 변동 폭
$3.49
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
명칭
Ardelyx Inc
전화
510-745-7047
주소
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.84 | 1.40B | 427.68M | -58.06M | -37.50M | -0.2382 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-09 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | 재개 | Raymond James | Strong Buy |
| 2025-06-18 | 재개 | H.C. Wainwright | Buy |
| 2025-05-02 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | 재개 | Ladenburg Thalmann | Buy |
| 2025-03-04 | 개시 | BTIG Research | Buy |
| 2024-11-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-18 | 개시 | Raymond James | Strong Buy |
| 2023-09-07 | 개시 | H.C. Wainwright | Buy |
| 2023-08-25 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-11-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-07-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-23 | 개시 | Wedbush | Outperform |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-20 | 재개 | Citigroup | Buy |
| 2020-02-18 | 재개 | Jefferies | Buy |
| 2020-02-12 | 개시 | Citigroup | Buy |
| 2020-02-10 | 개시 | Cowen | Outperform |
| 2019-04-08 | 개시 | Piper Jaffray | Overweight |
| 2018-08-24 | 개시 | Jefferies | Buy |
| 2018-03-19 | 재개 | Leerink Partners | Outperform |
| 2017-11-29 | 재확인 | Citigroup | Buy |
| 2017-11-22 | 재확인 | Ladenburg Thalmann | Buy |
| 2017-10-17 | 재개 | Leerink Partners | Outperform |
| 2016-03-31 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-09 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-03 | 개시 | Citigroup | Buy |
모두보기
Ardelyx Inc 주식(ARDX)의 최신 뉴스
ARDX (NASDAQ) insider sales: 125,000 shares notice; Raab 10b5-1 trades listed - Stock Titan
ARDX edges up after hours on IBSRELA momentum and profitability 'right around the corner' - MSN
ARDX Edges Up After Hours On IBSRELA Momentum And Profitability ‘Right Around The Corner’ - Stocktwits
Ardelyx (ARDX) Stock Valuation Check After Recent Share Price Volatility - Yahoo Finance
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? - Stocktwits
Ardelyx eyes $500M+ revenue as IBSRELA growth puts profitability within reach - MSN
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug - Stocktwits
Hyperphosphatemia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Ardelyx, Sanofi, Takeda Pharma, Unicycive Therapeutics, Taisho Pharma, Alebund Pharma - Barchart
ARDX Q1 2026 Earnings: Earnings Miss But Stock Gains as Investors Focus on Pipeline ProgressHigh Estimate Range - newsline.com
ARDX Q1 2026 Earnings: EPS Misses Estimates Slightly, Stock Gains Amid Mixed SignalsEarnings Revision Report - newsline.com
· SEC Filing - MLQ.ai
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Pullback And Growth Expectations - simplywall.st
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - TMX Newsfile
Ardelyx Advances Long-Term Tenapanor Trial in Chronic Constipation: What Investors Should Watch - TipRanks
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach - TradingView
ARDX: IBSRELA and XPHOZAH are set for robust growth, targeting $1B and $750M revenues by 2029 - TradingView
IBSRELA-Fueled Q1 Surge and AI Spotlight Could Be A Game Changer For Ardelyx (ARDX) - simplywall.st
ARDX Technical Analysis & Stock Price Forecast - Intellectia AI
Should You Buy Ardelyx (ARDX)? - Insider Monkey
What Triggered Ardelyx's Post-Earnings Plunge - Kavout
Ardelyx Inc. (ARDX) Q1 2026 Earnings: EPS Misses Estimates, but Stock Edges Higher Amid Strategic MomentumProduct Revenue Analysis - newsline.com
This Insider Has Just Sold Shares In Ardelyx - simplywall.st
Ardelyx Inc Live Share Prices and Trades. ARDX.US Live Streaming Share Prices. - London South East
Ardelyx (ARDX) price target increased by 12.82% to 13.46 - MSN
ARDX Q1 2026 Earnings: EPS Misses Estimates Amid Quiet Revenue DisclosureEarnings Surprise Score - newsline.com
Ardelyx chief patient officer sells $43,803 in shares By Investing.com - Investing.com Canada
Ardelyx chief patient officer sells $43,803 in shares - Investing.com
Tax-related Ardelyx (ARDX) insider sale covers RSU withholding needs - Stock Titan
Ardelyx (ARDX) CFO executes 1,455-share tax sell-to-cover after RSU vest - Stock Titan
Ardelyx (ARDX) officer’s RSU vesting triggers 2,306-share tax sell - Stock Titan
Ardelyx (ARDX) HR chief sells 1,846 shares to cover RSU taxes - Stock Titan
Ardelyx (ARDX) Chief Commercial Officer sells 7,998 shares to cover RSU taxes - Stock Titan
Ardelyx Inc (ARDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ardelyx Inc 주식 (ARDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reilly Joseph James | See Remarks |
May 21 '26 |
Sale |
6.27 |
3,719 |
23,309 |
149,107 |
| Hohenleitner Susan | Chief Financial Officer |
May 21 '26 |
Sale |
6.27 |
1,455 |
9,119 |
229,078 |
| Bishop John E | See Remarks |
May 21 '26 |
Sale |
6.27 |
2,306 |
14,453 |
336,845 |
| Brady James Parker | Chief Human Resources Officer |
May 21 '26 |
Sale |
6.27 |
1,846 |
11,570 |
261,066 |
| Foster Eric Duane | Chief Commercial Officer |
May 21 '26 |
Sale |
6.27 |
7,998 |
50,127 |
417,972 |
| Kelliher Mike | Chief Business Officer |
May 21 '26 |
Sale |
6.27 |
7,248 |
45,427 |
357,418 |
| Williams Laura A | Chief Patient Officer |
May 21 '26 |
Sale |
6.27 |
6,989 |
43,804 |
429,093 |
| RAAB MICHAEL | President & CEO |
May 21 '26 |
Sale |
6.27 |
54,748 |
343,133 |
1,720,033 |
2.60%
0.94%
자본화:
|
볼륨(24시간):